# Study of Ruxolitinib in the Treatment of Cachexia in Patients With Tumor-Associated Chronic Wasting Diseases.

> **NCT02072057** · PHASE2 · TERMINATED · sponsor: **Kantonsspital Aarau** · enrollment: 8 (actual)

## Conditions studied

- Cancer Cachexia

## Interventions

- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT02072057
- **Lead sponsor:** Kantonsspital Aarau
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-04-20
- **Primary completion:** 2018-11-30
- **Final completion:** 2018-11-30
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Poor recruiting
- **Last updated:** 2019-02-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02072057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02072057, "Study of Ruxolitinib in the Treatment of Cachexia in Patients With Tumor-Associated Chronic Wasting Diseases.". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT02072057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*